Company Overview of T2 Biosystems, Inc.
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products based on its proprietary platform. Its T2 Magnetic Resonance platform enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company offers T2Dx, a bench-top instrument, which has completed a pivotal clinical trial for performing diagnostic tests in sepsis and other applications; and T2Stat, an integrated instrument for hemostasis applications. It is also developing T2Candida panel that has completed a pivotal clinical trial for identifying pathogens associated with sepsis; T2HemoStat p...
101 Hartwell Avenue
Lexington, MA 02421
Founded in 2006
Key Executives for T2 Biosystems, Inc.
Chief Executive Officer
Total Annual Compensation: $350.0K
Chief Financial Officer and Chief Accounting Officer
Total Annual Compensation: $171.9K
Chief Operating Officer
Total Annual Compensation: $89.8K
Compensation as of Fiscal Year 2013.
T2 Biosystems, Inc. Key Developments
T2 Biosystems, Inc.(NasdaqGM:TTOO) added to NASDAQ Composite Index
Aug 8 14
T2 Biosystems, Inc. will be added to the NASDAQ Composite Index.
T2 Biosystems Seeks Acquisitions
Jul 2 14
T2 Biosystems, Inc. has filed an IPO in the amount of $69.00 million. T2 Biosystems intends to use the net proceeds to fund research and development programs, to obtain marketing authorization from the FDA, and support the commercialization of, our T2Dx and T2Candida product candidates, including the hiring of additional sales, marketing and manufacturing personnel and related support costs associated with sales, marketing and manufacturing activities, and the balance for other general corporate purposes, including general and administrative expenses, working capital, capital expenditures to add equipment for laboratory and manufacturing-related purposes and to support expansion of facilities, and the repayment of indebtedness.
T2 Biosystems Submits 510(K) Application to the FDA for Review of T2Dx and T2Candida
Jun 3 14
T2 Biosystems announced that it has filed a 510(k) premarket submission for T2Dx and T2Candida with the U.S. Food and Drug Administration (FDA). The premarket submission includes clinical trial and other data providing evidence that the T2Dx instrument and the T2Candida test panel may identify specific life-threatening sepsis-causing pathogens directly from an unpurified blood sample as fast as three hours, rather than the two to five days typically required for blood culture-based diagnostics.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|